title: The EWA (estrogen in women with atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipoproteins.
abstract: OBJECTIVE
  To evaluate the effects of hormone replacement therapy (HRT) on lipids and lipoproteins in postmenopausal women with coronary artery disease.
  
  
  METHODS
  In this single-centre, controlled and randomized study taking place in a tertiary referral clinic, patients were examined at baseline, and after 3 and 12 months. All analyses were performed examiner-blind.
  
  
  METHODS
  Postmenopausal women (n = 118) with angiographically verified coronary artery disease were recruited consecutively from patients referred for investigational procedures due to coronary artery disease.
  
  
  METHODS
  The women were randomized to HRT, i.e. transdermal application of continuous 17-beta oestradiol with cyclic medroxyprogesterone actetate tablets every 3rd month for 14 days, or to a control group.
  
  
  RESULTS
  Effects on lipids and lipoproteins.
  
  
  RESULTS
  After 3 months of unopposed oestradiol, triglycerides decreased significantly compared to the control group (P = 0.006). Sequential administration of medroxyprogesterone caused a decrease in HDL cholesterol (P = 0.01), concomitantly with a decrease in ApoA1 lipoproteins (P = 0.007). No other changes in lipids or lipoproteins were observed. After 12 months of therapy, no significant differences were observed between the two groups in lipid or lipoprotein levels. Concomitant statin treatment did not alter the main findings.
  
  
  CONCLUSIONS
  In postmenopausal women with established coronary artery disease in whom the majority is treated with statins, no additional effect of HRT on lipids or lipoproteins could be observed except for a transient decrease in triglycerides in the initial unopposed oestradiol phase. No deleterious effect could be observed during medroxyprogesterone administration except for a small transient decrease in HDL cholesterol and ApoA1 lipoproteins.
authors.affiliation: Department of Medicine, Ulleval University Hospital and Hormone Laboratory, Aker University Hospital, Oslo, Norway. ingrid.os@ulleval.no
authors.forename: I
authors.initials: I
authors.lastname: Os
authors.forename: A E
authors.initials: AE
authors.lastname: Hofstad
authors.forename: M
authors.initials: M
authors.lastname: Brekke
authors.forename: M
authors.initials: M
authors.lastname: Abdelnoor
authors.forename: B I
authors.initials: BI
authors.lastname: Nesheim
authors.forename: A F
authors.initials: AF
authors.lastname: Jacobsen
authors.forename: K
authors.initials: K
authors.lastname: Birkeland
authors.forename: A
authors.initials: A
authors.lastname: Larsen
authors.forename: K
authors.initials: K
authors.lastname: Midtbo
authors.forename: A
authors.initials: A
authors.lastname: Westheim
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004958:Estradiol / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D008055:Lipids; D008074:Lipoproteins; D004958:Estradiol; D017258:Medroxyprogesterone Acetate